Genprex, Inc. Commences Initial Public Offering And Sets Price
AUSTIN, Texas, Oct. 13, 2017 /PRNewswire/ -- Genprex, Inc., ("Genprex") a clinical stage gene therapy company, today announced that its initial public offering of a minimum of 2.5 million shares and a maximum of 4.5 million shares of its common stock has priced at $5.00 per share....
Read more »